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deposition in tissue of amyloid fibrils.
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Figure 1. Overlay of ribbon diagrams representing the
structures of wild-type human lysozyme (grey) and the
D67H (green) variant; the structure of the I56T variant is
indistinguishable from that of the wild-type protein.15
The a-helices are labelled A–D and the three 310 helices
are indicated. The four disulphide bonds are shown in red
and the amyloidogenic mutations I56T and D67H are
shown in blue. The black arrows indicate the relative
movements in the positions of residues 42–55 and 66–75
in the D67H variant compared to those of the wild-
type lysozyme. The lysozyme structures were generated
from coordinates determined by X-ray diffraction15
(PDB 1LYY, 1LOZ and 1LZ1) and produced using
MOLMOL.38
774 Reduced Cooperativity of Human Lysozyme VariantsIntroduction
The amyloidoses constitute a group of more than
20 human disorders that are characterized by the
pathological deposition in tissue of aggregated
forms of proteins or protein fragments. These
species include the Ab peptide (in Alzheimer’s
disease), the islet amyloid polypeptide (in type II
diabetes), transthyretin (in familial amyloidotic
polyneuropathy) and the prion proteins (in the
transmissible spongiform encephalopathies).1,2
Despite large variations in the amino acid
sequences and native structures of the peptides
and proteins associated with these diseases, the
general features of the aggregated species appear to
be closely similar to each other. They include
fibrillar morphologies and a common cross-b
structure in which the polypeptide chain forms
b-strands that are perpendicular to the long axis of
the fibril.3 Recent evidence has suggested that the
ability to form such structures, commonly known as
amyloid (or amyloid-like) fibrils, is a generic
property of peptides and proteins resulting from
stable interactions involving the main-chain atoms
that are common to all polypeptides.4–6 Thus, in
order to form amyloid fibrils, globular proteins
must first convert into precursor structures prone to
self-association in which a significant segment of
the polypeptide main chain is exposed to solvent.
Such exposure can occur through partial or com-
plete unfolding, which can be either at equilibrium
or transient, under solution conditions in which
stable intermolecular interactions can be formed.4,6,7
Exposure of the main chain and the hydrophobic
regions can also originate from partial degradation
as a result of, for example, proteolytic cleavage of
the polypeptide chain.8–10
The antibacterial protein lysozyme has been
found to be associated with a familial non-
neuropathic systemic amyloidosis in which large
quantities, sometimes kilograms, of aggregated
protein accumulate in organs such as the liver,
kidney, and spleen.11–13 The affected individuals are
heterozygotes with one of the single-point
mutations I56T, F57I, W64R or D67H, or the double
mutation F57I/T70N, in the gene coding for
lysozyme.11–13 The properties of the amyloidogenic
I56T and D67H variant proteins have been studied
extensively and compared with those of the wild-
type protein in order to examine how these
mutations affect properties such as activity, stability,
structure, folding, dynamics and aggregation.14–20
These two variant proteins have been found to have
native-state structures that are similar to that of
wild-type lysozyme and both are enzymatically
active.15 X-ray crystallography shows, however,
that the D67H mutation disrupts a series of
hydrogen bonds in the b-domain of the protein,
resulting in a significant movement of the b-sheet
structure and particularly the region containing
residues 42–55 and 66–75 (Figure 1).15 NMR studies
show that the D67H variant has a region of
substantially increased flexibility in the vicinity ofthe mutation (residues 65–80).18 Assuming that the
variant proteins form fibrils through a similar
mechanism, the structural changes and the greater
flexibility of a region of the b-domain in the native
state of the D67H variant do not, therefore, appear
to play a fundamental role in the aggregation
behaviour, because no change of similar magnitude
is observed for the I56T amyloidogenic variant
protein.15,18
Here, we report a detailed comparison of the
effects of the I56T and D67H mutations on the
stability, cooperativity and aggregation properties
of human lysozyme using a variety of techniques
including optical spectroscopy, and hydrogen/
deuterium (H/D) exchange experiments analyzed
by mass spectrometry (MS) and nuclear magnetic
resonance (NMR) spectroscopy. In addition, we
have used a variable domain of a camelid heavy
chain antibody (VHH)
21 raised against the native
state of wild-type lysozyme22 as a structural probe
to establish further links between the perturbations
of the molecular properties of the amyloidogenic
variants and changes in their propensity to convert
into amyloid fibrils. This study extends substan-
tially earlier investigation of these two amyloido-
genic variants by carrying out key experiments with
the I56T variant that were previously applied only
to the D67H variant,20 and by carrying out
experiments under identical conditions on both
variants in the presence and in the absence of the
camelid antibody fragment. The results of this
comparative study suggest that, despite their
different locations and different effects on the native
state of the lysozyme, the two mutations result in
very similar reductions of stability and global
Reduced Cooperativity of Human Lysozyme Variants 775cooperativity, conferring upon the protein variants
the capability of forming transiently closely similar
intermediate species under physiologically relevant
conditions. This specific reduction of global
cooperativity appears, therefore, to be the origin
of the in vivo amyloidogenicity of these two variants
of human lysozyme.Figure 2. (a) Electrospray mass spectra of a mixture of
[14N]I56T and 15N-labelled wild-type lysozyme. Mass
spectra were recorded for an equimolar mixture of 15N-
labelled wild-type lysozyme and the I56T variant follow-
ing exposure to hydrogen exchange conditions at pH 8.0
and 37 8C. The peaks observed in spectra of control
samples recorded after complete H/D exchange are
shown in black. The peaks coloured yellow were
observed in the spectra of the I56T variant but not in
that of the wild-type lysozyme. They result from a locally
cooperative unfolding event giving rise to exchange by an
EX1 mechanism. The peaks coloured red arise from the
gradual loss of deuterium during the course of exchange
that occurs via an EX2 mechanism.20 (b) Time-course of
the relative intensity of the lower mass species (peaks
coloured yellow in (a)) observed for the I56T variant
(filled circles). Fitting these data to an exponential
function (continuous line) indicates that the time constant
of the unfolding process is 32.6(G2.5) seconds. Data
obtained under similar conditions with the D67H
variant24 are included for comparison (open squares);
the time constant of the unfolding process for this variant
is 15.3(G0.6) seconds.Results
The I56T variant converts transiently into an
intermediate state similar to that populated by
the D67H protein
The effect of the I56T mutation on the stability
and global cooperativity of lysozyme was first
investigated by means of H/D exchange pulse-
labelling experiments, analyzed by mass spec-
trometry, using a procedure described previously
and used to study the D67H variant in detail.20
Because experiments of this type are highly
sensitive to small changes in solution conditions,
the I56T variant and the wild-type protein were
allowed to exchange simultaneously in the same
solution to enable a direct comparison of their
properties.23 By using uniformly 15N-labelled wild-
type protein and unlabelled [14N]I56T variant, the
molecular masses of the two proteins are suffi-
ciently distinct for their peaks to be resolved in
mass spectra during the H/D exchange experi-
ments. Both wild-type lysozyme and the I56T
variant were initially exposed to 2H2O (see
Materials and Methods) so as to replace all the
labile hydrogen atoms with deuterium atoms; the
exchange process therefore involved the replace-
ment of these deuterium atoms with hydrogen
atoms from the solvent H2O. The exchange was
carried out at pH 8.0 and 37 8C, and the reaction was
quenched at various time-points after the exchange
had been initiated by reducing the pH and
temperature of the solution.24
The data obtained from representative experi-
ments of this type are shown in Figure 2(a). The
wild-type protein is visible as a single peak
(coloured red on the right-hand side), whose mass
decreases with the length of time the exchange was
allowed to take place. This behaviour has been
shown to result from amide hydrogen atoms
undergoing exchange via an EX2 mechanism
through localized independent fluctuations of the
structure.20 The data for the I56T variant protein, by
contrast, show a clear bimodal distribution of
masses as exchange takes place (the red and yellow
peaks on the left-hand side of Figure 2(a)); this
behaviour is remarkably similar to that observed for
the D67H variant of lysozyme under similar
conditions.20,24 The additional peak (coloured
yellow on the left-hand side) results from amide
hydrogen atoms undergoing exchange via an EX1
mechanism, and indicates that locally cooperative
unfolding of a region of the protein occurs during
the time-scale of the experiment.20 The areas under
Figure 3. 15N–1H HSQC NMR spectra of the I56T variant lysozyme recorded (a) immediately after exposure to 2H2O
and, (b) after 3.5 hours of exchange at pH 5.0 and 37 8C. For comparison, (c) and (d) show the previously published
15N–1H HSQC NMR spectra of the D67H variant lysozyme recorded respectively immediately after exposure to 2H2O
and after 3.5 hours of exchange.20 Amide peaks visible immediately after exposure are labelled in (a) and (c), and the
776 Reduced Cooperativity of Human Lysozyme Variants
Reduced Cooperativity of Human Lysozyme Variants 777the two peaks in the mass spectra were integrated
and the fraction of the lower mass species calcu-
lated as a function of time; the time-course of the
relative intensity of this peak then provides a direct
measure of the opening rate of the cooperative
fluctuations giving rise to the exchange. The time
constant of the opening event for the I56T protein
was determined in this manner to be 32.6(G2.5)
seconds, a value of the same order of magnitude as
that determined for the D67H protein under the
same conditions (15.3(G0.6) seconds, Figure 2(b)).24
In order to obtain more residue-specific infor-
mation about the structure of the intermediate state
populated by the I56T variant, a series of 2D NMR
experiments was carried out to probe the H/D
exchange kinetics of individual amide groups. The
experiments were carried out by dissolving the
15N-labelled proteins in 2H2O at pH 5. This pH
value was chosen because under these conditions,
the intrinsic exchange rates of amide hydrogen
atoms are close to their minimum values. Therefore,
it should allow the maximum number of amide
hydrogen atoms to be observed in a series of 15N–1H
heteronuclear single quantum coherence (HSQC)
NMR spectra recorded while hydrogen exchange is
taking place. At the earliest acquisition time
following the initiation of the H/D exchange
reaction, cross-peaks from 78 amide hydrogen
atoms are visible in the HSQC spectrum from the
I56T variant (Figure 3(a)); this number is very
similar to that observed for the wild-type protein
(79 peaks),20 and somewhat higher than that
observed for the D67H variant (66 peaks,
Figure 3(c)).20 This number, however, depends
critically on the exact length of time taken to record
the first spectrum after the initiation of the exchange
process, since amide protons with relatively low
protection factors will exchange within the first half
hour. The spectra recorded after 3.5 hours illustrate,
however, qualitative differences in the H/D
exchange behaviour of the I56T variant from that
of wild-type lysozyme. The I56T variant has only 32
amide protons that have not exchanged signifi-
cantly after this length of time (Figure 3(b)),
whereas the wild-type protein has 50;20 for com-
parison, the D67H variant has 27 (Figure 3(d)).20 To
obtain quantitative information on the exchange
rates, we analyzed the height of individual cross-
peaks in the spectra as a function of the time of
exchange; the rates resulting from this analysis
were then used to obtain individual protection
factors.25 The ratios of the protection factors of the
wild-type protein to those of the I56T variant permit
a residue-specific comparison of the H/D exchangeamides that have not exchanged after 3.5 hours are labelled in
protection factors of the I56T variant with those of the wild-ty
K1 for the residues that did not show significant exchange d
type protein and the variant. Amides whose exchange rates are
protein are all located in the b-domain and the C-helix. A
conditions are shown for comparison.20 The right-hand pane
and D67H variants relative to that of the wild-type protein (Wbehaviour of the two proteins to be made
(Figure 3(e)). The results show that the effects of
the I56T mutation on the hydrogen exchange
behaviour are predominantly on amide protons
from residues in the b-domain (defined as contain-
ing residues 41–89) and the following C-helix
(residues 90–100). Remarkably, despite the different
structural localization of the mutations, these
results are almost identical to those obtained for
the D67H protein,20 which are shown for compari-
son in Figure 3(c)–(e).Binding of an antibody fragment stabilizes the
native state of the I56T variant
We have shown that the binding of cAb-HuL6, a
camelid antibody fragment21 raised against wild-
type lysozyme,22 acts to inhibit dramatically the
in vitro formation of amyloid fibrils by the D67H
variant by stabilizing the variant protein so that it is
no longer able to populate the transient inter-
mediate to a detectable level under the conditions
used in this study.24 Here, we investigated whether
the binding of the antibody fragment has a similar
effect on the properties of the I56T amyloidogenic
variant. Because experiments of this type are very
sensitive to small changes in solution conditions,
the behaviour of I56T and D67H variants was
studied in parallel experiments under identical
conditions.
We first measured the dissociation constant (KD)
for binding of the antibody fragment to the I56T
variant. We found a KD of 0.6 nM, a value very
similar to those measured for the wild-type lyso-
zyme (0.7 nM)22 and the D67H variant (1.2 nM).24
The site at which the antibody fragment binds to the
I56T variant was then mapped using NMR experi-
ments. Comparison of the 15N–1H HSQC NMR
spectrum of the free I56T protein, uniformly
labelled with 15N, with the spectrum of the 15N-
labelled protein complexed to the unlabelled
antibody fragment allows the binding region to be
probed in a site-specific manner by analysis of the
chemical shift perturbations of the resonances of the
amide groups of individual residues (Figure 4(a)).24
Despite the relatively high molecular mass of the
complex (about 28 kDa), a very well resolved
spectrum was obtained, enabling essentially all
the amide resonances to be identified (Figure 4(a)).
Analysis of the perturbations of the chemical shifts
reveals that the resonances of 30 residues exhibit a
significant chemical shift perturbation
(jDd1HjR0.1 ppm or jDd15NjR0.4 ppm) upon bind-
ing to the antibody fragment (Figure 4(c)). This(b) and (d). (e) The left-hand panel shows a comparison of
pe protein. The ratio of the protection factors is plotted as
uring the time-course of the experiment in both the wild-
accelerated bymore than tenfold relative to the wild-type
gain, data for the D67H variant obtained under similar
l shows a comparison of the protection factors of the I56T
T).
Figure 4. Overlaid 15N–1H HSQC NMR spectra of (a) the free I56T variant (blue) and the I56T variant complexed to
cAb-HuL6 (red), (b) the free D67H variant (blue) and the D67H variant complexed to cAb-HuL6 (red). The spectra were
collected at pH 6.5 and 35 8C. Residues experiencing a chemical shift changeRj0.4j ppm for 15N orRj0.1j ppm for 1H
resonances are considered to be affected significantly by the binding of cAb-HuL6 and are labelled. (c) Chemical shift
perturbations induced by the binding of cAb-HuL6 to I56T lysozyme. The pink and blue bars indicate the chemical shift
perturbations of the 1H and 15N resonances, respectively. The peak corresponding to residue 78 in the I56T-cAb-HuL6
complex has not been assigned; therefore shift differences for this peak are not shown in the histogram. No unassigned
peaks are visible in the spectra of the complex within 0.1 ppm (1H) and 0.4 ppm (15N) of the peak position of this residue
in the spectrum of the unbound protein. This finding suggests strongly that there are large chemical shift perturbations
for this residue in the complex. (d) Ribbon diagram of the I56T variant showing the Ca atoms of the residues affected
significantly by the binding of cAb-HuL6 in space-filling representation. Residues affected only in the I56T variant are
shown in pink, those affected only in the D67H variant are shown in blue, and residues affected in both variants are
shown in green. The region of the molecule that unfolds transiently in a locally cooperative manner is coloured yellow.
The lysozyme structure was generated from the X-ray coordinates (PDB entry 1LOZ)15 and produced usingMOLMOL.38
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protein (29, Figure 4(b)) and the wild-type protein
(31).24 The residues that are affected by the binding
of the antibody fragment are located in the loop
between the A and B helices in the a-domain, in the
long loop within the b-domain and in the C-helix
(Figure 4(d)) and include all the residues that have
been found to be in direct contact with the antibody
fragment in the crystal structure of the complex
with the wild-type lysozyme.24 The epitope for theI56T variant protein is therefore closely similar to
that for the D67H variant and for wild-type
lysozyme.24 This finding is completely consistent
with the very similar values of the dissociation
constants for the three lysozyme species, and with
the fact that the mutated residues are not located in
the epitope region, as we discuss below.
We then investigated the ability of the antibody
fragment to inhibit the formation of fibrils by the
two lysozyme variants when incubated at pH 5.0
Figure 5. (a) Time-course of the aggregation of the I56T and D67H variant lysozymes in the absence ( and for the
I56T and D67H variants, respectively) and presence of an equimolar quantity of cAb-HuL6 ( and for the I56T and
D67H variants, respectively) as monitored by light-scattering. Data are shown also for wild-type lysozyme in the absence
of cAb-HuL6 ( ). Inset: expansion to demonstrate the lag phase at the onset of the aggregation process. The lysozyme
concentration was 0.1 mg/ml and the data were recorded at 65 8C and pH 5.0. (b) Representative images of fibrils
produced by transmission electron microscopy. Left-hand panel, I56T variant; right-hand panel, D67H variant. The scale
bars represent 200 nm.
Reduced Cooperativity of Human Lysozyme Variants 779and 65 8C whilst the solutions were stirred. These
conditions differ from those used previously,24 and
have the advantage of enabling aggregation to be
monitored without the need for addition of a
chemical denaturant. In the absence of the antibody
fragment, both variant proteins aggregate within a
few minutes under these conditions (Figure 5(a)).
The kinetics of aggregation are similar for the two
variants and follow a sigmoidal curve consistent
with the nucleation-dependent growth model that
has been suggested as a common mechanism of
fibril formation.26 In contrast, when wild-type
lysozyme was incubated under the same con-
ditions, no significant increase in light-scattering
was observed, indicating that no detectable aggre-gation had taken place. The presence of large
quantities of fibrillar material in the aggregates
formed by both variant proteins was confirmed
unambiguously by negative-stain transmission
electron microscopy (Figure 5(b)). The structures
observed include a proportion of well-resolved
isolated fibrils, although the fibrils generally appear
to be incorporated into large bundles. Such struc-
tures have been observed with the D67H variant
when incubated in different conditions (pH 5.5 in
the presence of 3 M urea and at 48 8C).24 When the
variant proteins were incubated in the presence of
an equimolar amount of the antibody fragment, no
significant change in light-scattering was detectable
during the first two hours of incubation. After
Figure 6. Thermal unfolding (a) monitored by far-UV
CD at 228 nm, (b) monitored by ANS fluorescence at
475 nm. ( ) Free I56T variant; ( ) free D67H variant; ( )
I56T variant complexed to cAb-HuL6; ( ) D67H variant
complexed to cAb-HuL6; ( ) free wild-type lysozyme.
The lysozyme concentration was 0.2 mg/ml and
0.035 mg/ml in 0.1 M sodium acetate buffer (pH 5.0) for
CD and ANS fluorescence measurements, respectively.
A.U., arbitrary units.
780 Reduced Cooperativity of Human Lysozyme Variantslonger incubation times, however, a slow increase in
light-scattering was observed for both variants. This
increase is, however, likely to be due to the
somewhat reduced stability of the antibody
fragment under these conditions, as an increase in
light-scattering was observed when the antibody
fragment was incubated alone under the same
conditions. Taken together, these results indicate
clearly that the binding of the antibody fragment to
the variant proteins decreases their rate of aggrega-
tion significantly.
The effects on the equilibrium thermal unfolding
behaviour of binding the antibody fragment to the
variant proteins under the solution conditions
(0.1 M sodium acetate buffer, pH 5.0) used to form
fibrils were then investigated (Figure 6). Thermal
denaturation experiments followed by far-UVcircular dichroism (CD) (Figure 6(a)) indicate that
the temperatures of the mid-points of unfolding of
the I56T and D67H variants are very similar (TmZ
68(G1) 8C in both cases). This value is about
10 deg. C lower than that of the wild-type protein,
(TmZ80(G1) 8C) under similar conditions. In the
presence of the antibody fragment, however, the
stability of the variant proteins is raised by about
10 deg. C (TmZ78(G1) 8C), so that when com-
plexed to the antibody fragment the variant
proteins are almost as stable as the wild-type
protein. Moreover, the thermally induced
unfolding of both the I56T and D67H variants was
found to be associated with a substantial increase in
the intensity of the fluorescence of 8-anilino-1-
naphthalene-sulfonic acid (ANS) at 475 nm
(Figure 6(b)) with a maximum at 66(G2) 8C, very
close to the mid-point of unfolding. This finding
indicates that a partially unfolded intermediate is
populated significantly during unfolding, as
8-anilino-1-naphthalene-sulfonic acid (ANS) binds
to accessible hydrophobic clusters in proteins.
A much smaller enhancement of ANS fluorescence,
at 75(G2) 8C, was observed when the variant
proteins were heated in the presence of an
equimolar amount of the antibody fragment,
suggesting that partially unfolded structures at the
mid-point of denaturation are populated only
marginally in the presence of the antibody frag-
ment. An increase of similar amplitude in the ANS
fluorescence was observed at 78(G2) 8C with the
wild-type protein in the absence of the antibody
fragment, suggesting that it too could populate
some form of partially structured state close to its
denaturation temperature (Figure 6(b)).
The effects of the mutations on the dynamic
properties of the variant proteins under much
milder denaturing conditions were studied by
means of H/D exchange experiments analyzed by
MS and NMR. In a first set of experiments, real-time
H/D exchange kinetics under EX2 conditions
(pH 5.0, 37 8C) were monitored for the free
amyloidogenic variants and for the proteins com-
plexed with the antibody fragment (Figure 7(a) and
(b)). Under EX2 conditions, the rate at which any
unfolded regions of structure return to their
protected state is much faster than the intrinsic
exchange rate.27 This type of process results in the
observation of a single peak whose mass decreases
with the length of time the exchange is allowed to
take place and allows the number of protected sites
to be determined.15 In the absence of the antibody
fragment, about 31 and 32 residues for the I56T and
D67H proteins, respectively, are observed by MS to
be protected strongly after 3.5 hours; this number is
consistent with data obtained from the NMR
measurements under the same conditions (32 and
27 amide protons for the I56T and D67H variants,
respectively; Figure 3(b) and (d)). In the presence of
the antibody fragment, however, about 48 and 51
residues are observed by MS to be protected
strongly in the I56Tand D67H proteins, respectively
(Figure 7(a) and (b)) a number in good agreement
Figure 7. Kinetic profiles of
hydrogen exchange at pH 5.0,
37 8C monitored by mass spec-
trometry: (a) for I56T lysozyme
(C) free and (B) complexed to
cAb-HuL6. (b) Equivalent data
obtained for the D67H protein
free (C) and (B) complexed to
cAb-HuL6. (c) Pulse-labelling
H/D exchange at pH 8 and 37 8C
of a mixture of I56T variant and
15N-labelled wild-type lysozyme
in the absence (left-hand panel)
and in the presence (right-hand
panel) of cAb-HuL6. The peaks
coloured yellow in the spectra of
the I56T variant (left-hand panel)
and that result from a locally
cooperative unfolding event,20 are
not observed in the spectra of the
I56T protein in the presence of the
antibody fragment (right-hand
panel).
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NMR under similar conditions (50).20
In a second set of experiments, the effects of the
mutations on the variant proteins was investigated
by H/D exchange pulse-labelling experiments
under conditions where an EX1 exchange mechan-
ism has been observed for both variants
(Figure 2(a)).20,24 Under these conditions (pH 8.0
and 37 8C), the refolding rate of any fluctuation
enabling hydrogen exchange to take place is much
slower than the intrinsic exchange rate; effectively
all the labile hydrogen atoms that are exposed will
undergo exchange each time such a fluctuation
occurs. Thus, if a fluctuation results in the coopera-
tive unfolding of a significant region of the protein
molecule, a well-resolved bimodal distribution of
masses should result; the two peaks represent the
populations of molecules that have or have not
experienced such a cooperative fluctuation
(Figure 7(c)).20 An equimolar mixture of the I56T
variant and 15N-labelled wild-type protein was then
incubated in the presence of a stoichiometric
amount of the antibody fragment (i.e. I56T:WT:cAb-
HuL6Z1:1:2). Exchange was carried out for
45 seconds and 120 seconds (i.e. the lengths of
time necessary for about 50% and 75%, respectively,
of the I56T protein molecules to access, at least once,
the partially unfolded state in the absence of the
antibody fragment; Figure 2(b)). The peak at lower
mass that is observed for the I56T protein in the
absence of the antibody fragment (the peak
coloured yellow in the left-hand panel in
Figure 7(c)), and which results from the transient
unfolding of the b-domain and the C-helix, is not
seen in the spectra obtained in its presence (theright-hand panel in Figure 7(c)). Indeed, the I56T
protein in the presence of the antibody fragment is
visible as a single peak, whose mass decreases
steadily as the length of time that exchange was
allowed to take place increases; this situation
indicates that the exchange process occurs through
localized independent fluctuations of the structure
through an EX2 mechanism. Thus, in the presence
of the antibody fragment, virtually none of the
lysozyme molecules transiently access the locally
cooperative unfolded species within the duration of
the exchange experiment. A similar inhibition of the
transient partial unfolding on the binding of the
antibody fragment has been reported for the D67H
protein.24
Finally, a series of 2D NMR experiments was
carried out to monitor in a site-specific manner the
hydrogen exchange behaviour of both the
amyloidogenic variants in the presence and in the
absence of the antibody fragment. These experi-
ments were carried out at pH 6.5 and 35 8C to
ensure that the antibody binds tightly to the
lysozyme molecules. Both variants of human
lysozyme showmuch less protection against hydro-
gen exchange than the wild-type protein; about ten
amide protons are protected in both variant
proteins compared to 23 in the wild-type protein
after 13.2 hours of exchange (Figures 8(b), and 9(b)
and (f)). Moreover, none of the b-domain or C-helix
amide protons is observed to be protected in the
I56T and D67H variant proteins under these
conditions.The partial unfolding observed at
pH 5.0 and 37 8C (Figure 3(b)) therefore occurs
also at pH 6.5 and 35 8C. The formation of a complex
between the variant proteins and the antibody
Figure 8. 15N–1H HSQC NMR spectra of ((a) and (b)) free I56T variant lysozyme; ((c) and (d)) the I56T variant in the
presence of a stoichiometric amount of cAb-HuL6; ((e) and (f)) the I56T variant in the presence of a stoichiometric
amount of an unrelated antibody fragment (cAb-R2). The spectra were collected immediately after exposure to 2H2O
(top) and after 13.2 hours (bottom) of exchange at pH 6.5 and 35 8C. Amide peaks are labelled in the last spectrum in
which they are visible.
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exchange behaviour, with a significant retardation
of the exchange rates of the b-domain and C-helix
amide protons (Figures 8(d) and 9(h)). In the
presence of an antibody fragment that does not
interact with lysozyme, cAb-R2,22 the hydrogen
exchange behaviour of the I56T variant protein is,
however, nearly identical with that observed with
the free protein (Figure 8(f)). This finding confirms
that it is the specific binding of the cAb-HuL6
fragment that is responsible for the inhibition of the
partial unfolding event. Taken together, these
results demonstrate that in the presence of the
antibody fragment, both amyloidogenic variants of
lysozyme studied here display a behaviour vir-
tually identical with that of the wild-type protein in
its absence. The interaction of the variant proteins
with the antibody fragment must, therefore, lead to
a stabilization of the native conformation of the
protein and, effectively, completely suppresses the
partial unfolding event triggered by the mutational
changes in the amino acid sequence.Discussion
The amyloid diseases are characterised by the
extracellular accumulation of protein aggregates
that share a common fibrillar conformation. These
disorders include Alzheimer’s and the prion
diseases, and type II diabetes.1,2 Moreover, diseasesare being added to the list each year, as tests
reveal the presence of amyloid deposits in
conditions such as amyotropic lateral sclerosis and
some forms of arterial amyloidoses.2 Most of the
diseases associated with protein aggregation are
strongly age-dependent or related to modern life-
styles; they are therefore becoming increasingly
prevalent.28 Alzheimer’s disease and type II
diabetes, for example, are rapidly becoming the
most costly and socially disruptive diseases in the
developed world.29 No effective treatment for this
type of disease is available so far, although
extensive research is being done to address the
question of their prevention and therapy.30 Under-
standing the mechanism and molecular details of
the pathological conversions of amyloidogenic
proteins from their soluble forms into fibrillar
structures is of crucial importance for this
objective.31
In this study, we have investigated and compared
the effect of two natural amyloidogenic mutations
on the properties of human lysozyme. The molecu-
lar details that we have been able to gain in this
study show that the two variant proteins behave in
an astonishingly similar manner, despite the fact
that the two mutations are sequentially and
spatially distinct, and have different effects on the
native-state structure and dynamics.15,18 Equi-
librium thermal unfolding experiments show that
both variants are less stable than the wild-type
protein (by about 10 deg. C) as reported.15,24 Most
Figure 9. 15N–1H HSQC NMR spectra of ((a) and (b)) free wild-type lysozyme; ((c) and (d)) wild-type lysozyme in the
presence of a stoichiometric amount of cAb-HuL6; ((e) and (f)) free D67H variant protein; ((g) and (h)) the D67H variant
in the presence of a stoichiometric amount of cAb-HuL6. The spectra were collected immediately after exposure to 2H2O
(top) and after 13.2 hours (bottom) of exchange at pH 6.5 and 35 8C. Amide peaks are labelled in the last spectrum in
which they are visible.
Reduced Cooperativity of Human Lysozyme Variants 783
784 Reduced Cooperativity of Human Lysozyme Variantsimportantly, their unfolding is substantially less
cooperative than the wild-type protein under the
conditions studied here. H/D pulse-labelling
experiments reveal that the two variant lysozymes
can populate an intermediate transiently under
conditions that include physiologically relevant
values of pH and temperature, where the proteins
are otherwise stable. Interestingly, the present work
demonstrates that the region of the protein struc-
ture that is unfolded transiently is effectively
identical in the two variant proteins. In this
intermediate species, the b-domain and the adjacent
C-helix are unfolded cooperatively, whereas the
remainder of the a-domain appears to be largely
native-like in structure (Figure 4(d)). The time-scale
on which these fluctuations occur is very slow
relative to most fluctuations occurring in protein
structures, and is of the same order of magnitude
in the two variants (32.6(G2.5) seconds and
15.3(G0.6) seconds for the I56T and D67H proteins,
respectively, see above).
The remarkable similarity in the behaviour of the
I56T and D67H variant proteins can be rationalized
from structural data,15 which suggest that in both
variants the crucial interface region between the a
and b-domains is less constrained than in the wild-
type protein, and that this perturbation of the
interface is likely to be the origin of the reduction
in global cooperativity. Interestingly, the inter-
mediate that is sampled occasionally by the variant
proteins resembles that populated in the normal
refolding of the protein from a highly denatured
state,20,32 emphasising the close link between
normal and aberrant folding behaviour. A recent
important observation is that for hen egg-white
lysozyme, a protein homologous to human lyso-
zyme with 60% sequence identity, fragments corre-
sponding to part of the b-domain and all the
residues of the C-helix, are cleaved readily from
the protein by proteolysis when incubated at low
pH and high temperature. Moreover, these frag-
ments form amyloid fibrils rapidly,33 in contrast to
fragments corresponding to the remainder of the
a-domain, which remain largely soluble under the
same conditions.33 This result indicates that
the region corresponding to the b-domain and
C-helix has a high intrinsic propensity to aggregate.
Thus, it is likely that, following exposure to the
solvent as the result of partial unfolding, this region
of the variant proteins readily initiates the aggrega-
tion event that ultimately leads to the formation of
fibrils. This highly amyloidogenic character of the
destabilized region is probably the reason why all
the known amyloidogenic mutations are localised
in the b-domain.
Furthermore, we have shown that binding a
camelid antibody fragment to both the I56T and
D67H variant proteins inhibits dramatically their
ability to aggregate in vitro and to form amyloid
fibrils. In addition, in the presence of the antibody
fragment, virtually none of the molecules of the
I56T (this work) and D67H22 variant proteins
undergoes even a single locally cooperativeunfolding event on the time-scale of the experiment
(up to one hour). These results indicate that the
frequency of such fluctuations in both variants is
reduced drastically as a result of binding to the
antibody fragment. Real-time MS and NMR exper-
iments have further confirmed that the binding of
the antibody restores the high degree of global
cooperativity that is characteristic of the wild-type
protein. These results therefore provide further
evidence that the formation of a partially unfolded
species with a high propensity to aggregate,
resulting from the locally cooperative unfolding of
the b-domain and the C-helix, is the critical event
that triggers the aggregation process in the absence
of the antibody fragment. Our previous structural
study of the complex between the wild-type protein
and the antibody fragment revealed that the epitope
includes neither the site of the mutation nor most of
the residues in the region of the protein structure
that is destabilized by the mutations.24 Thus, the
effects of binding are not simply to mask the entire
region of the protein destabilised by the mutation
and hence to prevent its unfolding from the
remainder of the structure. Rather, it appears that
the binding of the antibody fragment restores the
global cooperativity of the lysozyme structure that
is disrupted by these two amyloidogenic mutations
by a more subtle mechanism. It is of particular
interest to note that perturbations to the NMR
chemical shifts of the I56T protein upon the binding
of the antibody fragment include the amide
resonance of residue 57. The amide resonance of
this residue, which is located at the interface of the
two domains and is itself the location of an
amyloidogenic mutation,13 is perturbed signifi-
cantly as a result of the binding of the antibody
fragment to the D67H protein.24 Restoration of the
global cooperativity therefore occurs, at least in
part, through the transmission of long-range con-
formational effects to the interface between the two
structural domains of the protein in a process
reminiscent of the final step in the normal folding
process.16,32
Taken together, these results suggest that the
disruption of the interface region between the a and
b-domains is a crucial event in determining the
amyloidogenicity of the variant proteins. Moreover,
the observation that an antibody fragment can
restore behaviour characteristic of the wild-type
protein supports the idea that such species could be
important leads in the search for therapeutic
strategies.34 Although our results provide a clue
as to the possible significance of partially folded
species in amyloidogenicity, they raise the issue of
the possible importance of the specific structure of
the intermediate, which is similar for the two
amyloidogenic proteins, in the formation and the
structure of the resulting amyloid fibrils. The
common, perhaps universal, ability of polypeptides
to form amyloid fibrils with similar morphological
properties indicates that the specific structure of the
partially folded intermediate formed by amyloido-
genic variants is unlikely to be critical in defining
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fibrillar assembly.20 The properties of the inter-
mediate are, however, likely to be extremely
important in determining the regions of the poly-
peptide chain involved in the core of the cross-b
structure and in defining the properties and rates of
formation of the initial oligomers that ultimately
form the mature fibrils. In particular, in the case of
lysozyme, the high propensity of the most unfolded
regions of the intermediate state to convert into
amyloid fibrils is likely to be a crucial factor in the
high amyloidogenicity of the protein. Thus,
mutations causing amyloidosis are likely to be
those that do not destabilize the protein sufficiently
to trigger their destruction in endoplasmic reticu-
lum-associated degradation (ERAD) process, but
disrupt the global stability and cooperativity to
such an extent that an intermediate is populated in
which the partial unfolding event exposes a highly
aggregation-prone region of the protein sequence.
These results demonstrate clearly the link
between the ability of the amyloidogenic variant
proteins to populate an intermediate that results
from the perturbation of the structure of the
interface between the two lysozyme domains and
their propensity to convert into amyloid fibrils. In
the native state of a globular protein, the higher
cooperativity of the overall fold under physiological
conditions locks the polypeptide chain within the
folded structure and thus prevents the develop-
ment of intermolecular interactions involving the
majority of the main chain or of hydrophobic
residues.5 Fluctuations in the native structure that
can give rise to hydrogen exchange but expose
transiently only very local regions of the poly-
peptide chain to the solvent are unlikely to generate
conformations of a protein able to form strong
intermolecular interactions. If such fluctuations
expose significant regions of the polypeptide main
chain and its hydrophobic core, however, they
could represent an initial step in the development
of intermolecular interactions whereby near-native
like aggregates form prior to the formation of
extensive region of b-sheet structure; such species
have indeed been observed in other systems during
the early stages of aggregation.35
In accord with this concept, conditions that
readily stimulate formation of amyloid fibrils are
generally those that at least partially denature the
protein and expose substantial regions of the
polypeptide backbone to the solvent. This unfold-
ing event may in some cases arise from the global
unfolding of the native structure, or from local
cooperative unfolding as in the case with the
amyloidogenic lysozyme studied here.1 Indeed,
for the I56T and D67H variants, the population of
a partially unfolded intermediate is much greater
than for the wild-type protein under similar
conditions and the local cooperativity of the
unfolding process that generates the intermediates
results in most of the b-domain and C-helix being
unfolded simultaneously, under conditions where
the native state is otherwise stable. Moreover, theregion exposed in this way is highly amyloidogenic,
as shown by the study of the fragment of hen egg-
white lysozyme.33 This combination of factors could
give rise to a sufficient concentration of soluble,
partially folded species capable of forming signifi-
cantly strong intermolecular interactions to initiate
aggregation under much milder conditions than
would be needed to generate a similar concen-
tration of partially unfolded molecules for the wild-
type protein. Such species may then convert into
large aggregates with more extensive b-sheet
structure characteristic of amyloid fibrils. This
conclusion reinforces the view that the remarkable
cooperativity of native protein structures is an
essential evolutionary development to enable other-
wise marginally stable structures to resist aggrega-
tion under conditions in which they exert their
biological function.5Materials and MethodsProteins
Wild-type human lysozyme and its I56T and D67H
variants, including uniformly 15N-labelled proteins,
cAb-R2 and the cAb-HuL6 were expressed and purified
as described.22,36 The affinity of cAb-HuL6 for the
lysozyme species was determined using surface plasmon
resonance as described.22Electron microscopy
Samples were applied to Formvar-coated nickel grids,
stained with 2% (w/v) uranyl acetate solution and
viewed in a Philips CEM100 transmission electron
microscope operating at 80 kV.Aggregation monitored by right-angle light-scattering
Stock solutions of the proteins were prepared from
lyophilized material, passed through a 0.22 mm pore size
filter, diluted to the desired final concentration into 0.1 M
sodium acetate buffer (pH 5.0) and incubated at 65 8C
with stirring in a Cary Eclipse spectrofluorimeter. The
excitation wavelength was 500 nm and changes in
fluorescence emission were monitored at 500 nm with
slit-widths of 5 nm.Fluorescence measurements
ANS fluorescence was recorded on a Cary Eclipse
spectrofluorimeter equipped with a four-cell Peltier
holder with excitation and emission wavelengths of
350 nm and 475 nm, respectively. The excitation and
emission slit-widths were both 5 nm. The protein con-
centration was 2.4 mM in a 1 cm path-length cuvette and
the final concentration of ANS was 315 mM as determined
from the molar extinction coefficient of 4950 MK1 cmK1.
The buffer was 0.1 M sodium acetate (pH 5.0) and the data
were corrected for the background fluorescence of the
solution in the absence of the protein (bufferCANS). The
temperature was increased monotonically from 5 8C to
97 8C at a rate of 0.5 deg. C/minute.
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Heat-induced unfolding transitions were monitored by
far-UV CD using a Jasco J-810 spectropolarimeter
equipped with a six-cell Peltier holder with a 0.1 cm cell
path-length. The protein concentration was 0.2 mg/ml in
0.1 M sodium acetate buffer (pH 5.0), based on A280
1%Z2.5
and 2.1 for lysozyme and cAb-HuL6, respectively. The
temperature was increased monotonically from 25 8C to
97 8C at a rate of 0.5 deg. C/minute. Data were acquired
every 1 deg. C, with a four second integration time and a
2 nm bandwidth. The very low intensity of the far-UV CD
signal of the antibody fragment compared to that of the
human lysozyme, and the existence of only minor
changes at 228 nm upon unfolding of the cAb-HuL6,
enabled us to monitor specifically at that wavelength
the unfolding of lysozyme within the complex with
cAb-HuL6.Pulse labelling hydrogen/deuterium exchange of the
I56T variant analyzed by mass spectrometry
The [14N]I56T variant and uniformly 15N labelled wild-
type lysozyme were deuterated at exchangeable sites by
unfolding in deuterated guanidinium hydrochloride
followed by refolding in deuterated buffer (50 mM
deuterated acetic acid, pH* 5.0). The proteins were
subsequently concentrated and the buffer was changed
to 10 mM deuterated acetic acid, pH* 5.0, using Centri-
prep-3 concentrators (Amicon, Millipore) and mixed in
equal proportions. For the experiments in the presence of
cAb-HuL6, the deuterated lysozymes and protonated
cAb-HuL6 were mixed immediately before the experi-
ment was performed to give a stoichiometric ratio of
I56T:WT:cAbHuL6Z1:1:2. The pulse-labelling hydrogen
exchange experiments were carried out using a Bio-Logic
QFM5 mixer connected to a circulating water-bath set at
37 8C as described.20 One volume of protein solution was
mixed with 15 volumes of 100 mM ammonia/formic acid
buffer in H2O at pH 8.0, and the exchange was allowed to
proceed for various times between 0.4 second and
120 seconds. The resulting solutions were then mixed
with seven volumes of a 1 M acetic acid solution in H2O,
to generate a pH of 3.5 for the solutions after the quench
step. The samples were collected and placed on ice before
analysis by mass spectrometry. A control sample corre-
sponding to complete exchange was prepared by mixing
one volume of protein solution with 22 volumes of 20 mM
acetic acid/ammonia buffer in H2O at pH 5.0. This sample
was incubated for 15 minutes at 80 8C and subsequently
placed on ice. The samples were electrosprayed at the
base pressure of a Platform mass spectrometer (Micro-
mass, UK) and at a cone voltage of 150V. Under these
conditions, the antibody-lysozyme complexes dissociate
in the mass spectrometer, enabling the mass distributions
of the lysozyme molecules alone to be determined readily
and directly. Mass spectra shown in Figures 2(a) and 7(c)
represent the convolution of theC8,C9, andC10 charge
states with minimal smoothing and converted to a mass
scale. Data analysis was performed using Grams 32 V5.10
(Galactic Industries). The spectra were fitted to a linear
baseline and a combination of Gaussian distributions to
estimate the relative proportions of the different species.
The calculated areas for each peak from the fits were
analyzed as a function of time and used to extract kinetic
parameters for the exchange reactions using Sigmaplot
v5.0 (SPPS). No correction was made to the number of
exchangeable amide protons for the w5% deuteriumpresent in the labelling pulse, since back exchange does
not affect the relative proportions of each species.
Real-time mass spectrometry
Stock solutions of 200 mM wild-type, I56T and D67H
human lysozymes were prepared in MilliQ-prepared
water adjusted to pH 5.0 with formic acid. Exchange
was initiated by 20-fold dilution into 2H2O at pH* 5.0
(uncorrected for the deuterium isotope effect),
adjusted with deuterated formic acid at 37 8C. Spectra
were recorded before the initiation of exchange and at
various times during the exchange reaction. A
correction was made to the number of exchangeable
amide protons for the w5% deuterium present in the
labelling pulse.
Real-time 2D NMR spectroscopy of the 15N-labelled
I56T variant
The I56T variant protein (5 mg) was dissolved in 575 ml
of 20 mM acetic acid in 2H2O at pH 5.0* (value
uncorrected for the isotope effect). This pH value was
chosen because the intrinsic exchange rates of amide
hydrogen atoms are close to their minimum values.
Therefore, it should allow the maximum number of
amide hydrogen atoms to be observed in a series of
15N–1H-HSQC NMR spectra recorded while hydrogen
exchange is taking place. The exact pH values of the
samples were determined at the end of each experiment
and used in the calculation of protection factors.25 Series
of gradient-enhanced 15N–1H HSQC spectra were
collected at 37 8C in a 600 MHz NMR spectrometer.
Each spectrum took w30 minutes to record, with 96
complex t1 increments of eight transients and 1024
complex data points. Sweep-widths of 8000 Hz and
1825 Hz were used in the F2 and F1 dimensions,
respectively. The data were processed with a Gaussian
window function in F2 and a 908 shifted sine bell in F1
using the program Felix 2.3 (Accelrys). After zero filling,
the digital resolution was 3.9 Hz/point and 3.6 Hz/point
in F2 and F1, respectively. Hydrogen exchange rates were
monitored by measuring peak heights in the HSQC
spectra as a function of time. Sigmaplot v5.0 (SPPS) was
used to fit exponential functions to the data. The
predicted exchange rates for the same sequence in a
random coil conformation were divided by the experi-
mentally measured rates to calculate protection factors.
We used the published protection factors for the wild-
type lysozyme.20 For the residues that did not show
significant exchange during the time-course of the
experiment in both the I56T variant and the wild-type
protein, the ratio of the protection factors is plotted asK1
(Figure 3(e)). For the residues that did not show
significant exchange during the time-course of the
experiment for the wild-type protein but did for the
variant, we have used previous data for the wild-type
protein recorded at pH 5.5 and 35 8C for longer periods of
time.37 Additional 2D correlated spectroscopy (COSY)
and nuclear Overhauser effect spectroscopy (NOESY)
experiments were recorded, at 20 8C and 37 8C, of the
variant protein prepared in 2H2O or in H2O to obtain
assignments for the amide cross-peaks observed in the
HSQC spectra.
Real-time experiments were carried out at pH 6.5
and 35 8C for both variant proteins and wild-type
lysozyme in the absence and in the presence of the
antibody fragment in a home-built 750 MHz NMR
spectrometer belonging to the Oxford Centre for
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using a series of eight HSQC spectra using samples
(0.6 mM for the I56T variant and the wild-type protein
and 0.33 mM for the D67H variant) dissolved in
20 mM phosphate buffer (pH 6.5) in 2H2O (value
uncorrected for the isotope effect). When present the
antibody was added in 15% excess. The excess of
antibody ensured that all lysozyme molecules were
bound to the antibody molecule in the complex. Each
spectrum took w1.8 hours to record, with 128
complex t1 increments of 16 transients and 1024
complex data points. Sweep-widths of 10,582 Hz and
2273 Hz were used in the F2 and F1 dimensions,
respectively. The data were processed with a Gaussian
window function in F2 and a 908 shifted sine bell in
F1. After zero filling, the digital resolution was
5.2 Hz/point and 4.4 Hz/point in F2 and F1,
respectively.NMR studies of the I56T:cAb-HuL6 complex
An NMR sample of the complex was made containing
w0.7 mM unlabelled cAb-HuL6 and w0.6 mM 15N-
labelled I56T variant at pH 6.5 in 20 mM sodium
phosphate buffer made with 95% (v/v) H2O/5% (v/v)
2H2O. The excess of antibody concentration ensured that
all the lysozyme molecules were bound to an antibody
molecule in the complex. A 2D 15N–1HHSQC spectrum of
the I56T variant bound to the antibody fragment was
collected at 35 8C on the 750 MHz spectrometer. The
spectrumwas collected with 128 complex t1 increments of
64 transients and 1024 complex data points. Sweep-
widths of 10,582 Hz and 2273 Hz were used in the F2 and
F1 dimensions, respectively. The data were processed
with a Gaussian window function in F2 and a 908 shifted
sine bell in F1, using the program FELIX (Accelrys). After
zero filling the digital resolution was 5.2 Hz/point and
4.4 Hz/point in F2 and F1, respectively. The resonances
arising from the I56T protein in the complex were
assigned by comparison with the assigned spectrum of
the unbound protein18 and that of the wild-type protein in
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